MetaCap

Fortress Biotech (FBIO) vs Medicinova (MNOV)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Medicinova (MNOV) has outperformed Fortress Biotech (FBIO) over the past year, losing 8.4% versus a loss of 26.6%. Over five years, MNOV leads with a -59.3% price change compared with -95.5% for FBIO. Medicinova is the larger company by market cap ($67.1 million vs $64.1 million), about 1.0 times the size.

Fortress Biotech converts more of its revenue into profit, with a net margin of 10.8% versus -2928.8%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

FBIO-26.64%MNOV-8.39%
+150%+54%-43%
Nov 21, 20251 yearNov 20, 2026
FBIO-95.90%MNOV-59.19%
+8%-47%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

FBIO versus MNOV key metrics
MetricFBIOMNOV
Share price$1.90$1.31
Market cap$64.11M$67.11M
1-day change+7.34%+3.15%
YTD return-48.09%0.00%
1-year return-26.64%-8.39%
5-year return-95.52%-59.32%
P/E ratio (TTM)0.83—
EPS (TTM)$2.30$-0.21
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$63.26M$409.66K
Revenue growth (YoY)+9.69%—
Net income (latest FY)$6.82M$-12.00M
Gross margin66.92%—
Operating margin-111.00%-3242.47%
Net margin10.77%-2928.78%
52-week high$4.53$3.90
52-week low$1.64$1.22
Distance from 52-week high-58.06%-66.41%
Analyst consensusnonestrong_buy
Avg. price target upside+163.16%+529.77%
Average volume281.49K334.96K
Shares outstanding33.74M51.23M
Employees786
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • MNOV has outperformed FBIO by 18.2 percentage points over the past year.
  • Fortress Biotech is more profitable, keeping 10.8 cents of every revenue dollar as net income versus -2928.8 cents for Medicinova.

About Fortress Biotech

FBIO stock →

Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.

Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees

About Medicinova

MNOV stock →

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, and glioblastoma, as well as prevention of acute respiratory distress syndrome.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

FBIO vs MNOV FAQ

Which is bigger, Fortress Biotech or Medicinova?

Medicinova (MNOV) is larger, with a market capitalization of $67.11M compared with $64.11M for Fortress Biotech (FBIO).

Which stock has performed better over the past year, FBIO or MNOV?

MNOV returned -8.39% over the past 12 months, compared with -26.64% for FBIO (price return, excluding dividends). Past performance does not predict future results.

Are Fortress Biotech and Medicinova in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons